CDH1 and lung carcinoma: Interestingly, treatment with rosiglitazone repressed tumor metastatic potential in gastric cancer [76], inhibited EMT and metastasis by antagonizing TGF-β signaling in lung cancer [77], and suppressed metastasis in hepatocellular carcinoma by regulating metalloproteinases (MMPs) and E-cadherin [78].